Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/25/2024 | $300.00 → $310.00 | Overweight | Piper Sandler | |
9/10/2024 | $295.00 | Buy | Deutsche Bank | |
9/5/2024 | Peer Perform | Wolfe Research | ||
8/29/2024 | Outperform | William Blair | ||
7/24/2024 | $162.00 → $215.00 | Hold | Truist | |
7/24/2024 | $274.00 → $258.00 | Neutral | Citigroup | |
7/24/2024 | $248.00 → $230.00 | Neutral | Goldman | |
7/24/2024 | $205.00 → $300.00 | Overweight | Piper Sandler |
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
D - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company's management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert "Al" Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer. "I believe we have the team in place to successfully drive CERo forward into the clinic and to create the Company we have promised our shareholders. These new management team
MIAMI, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York City, including Wa'el Hashad, Chief Executive Officer, speaking on the panel "Emerging Frontiers in Neuroscience" and investor 1x1 meetings. The Longeveron investor presentation to be used at the conference is available at the "Events & Presentations" section of the Company's website. About Longeveron Inc. Longeveron is a cl
In the third quarter, we produced approximately 470,000 vehicles, delivered approximately 463,000 vehicles and deployed 6.9 GWh of energy storage products. Production Deliveries Subject to operating lease accounting Model 3/Y 443,668 439,975 3% Other Models 26,128 22,915 1% Total 469,796 462,890 3% Tesla will post its financial results for the third quarter of 2024 after market close on Wednesday, October 23, 2024. At that time, Tesla will issue a brief advisory containing a link to the Q3 2024 update, which will be available on Tesla's Investor Relations website. Tesla management will hold a live question and answer webcast that day a
To gain an edge, this is what you need to know today. GDP Brings Buying Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ. The drop in QQQ was triggered by speculative sentiment pulling back. As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold. Oversold markets tend to bounce. The chart shows that the volume was low on the selloff. This indicates a lack of conviction in selling. Especially hard hit in
Honda Motor Co. (NYSE:HMC) will reduce its production of gasoline vehicles in China by 19% starting this October, marking a strategic shift toward electric vehicles. The Japanese automaker will cease operations of one production line at its joint venture Dongfeng Honda, which has an annual capacity of 240,000 units, beginning in November. Additionally, in October, GAC Honda, another of its facilities with a capacity of 50,000 units annually, will be completely shut down. These changes are part of Honda's effort to accelerate the “steady shift” to EVs, reported Bloomberg. Honda’s production capacity in China, currently around 1.5 million units, will see a reduction of 19% due to
https://x.com/elonmusk/status/1816478001884004816https://x.com/elonmusk/status/1815907844434112999
MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte
MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, and who was appointed as the inaugural director of the
Tesla Is Now a Texas Corporation At today's Annual Stockholders' Meeting, Tesla stockholders overwhelmingly approved the ratification of the 2018 CEO Performance Award and the redomestication of the Company to Texas. Tesla has submitted all filings to effectuate its conversion into a Texas corporation and can confirm that the Company is now incorporated in Texas. Full voting results for its 2024 Annual Meeting of Stockholders are below. AGENDA ITEM PROPOSAL BOARD VOTE RECOMMENDATIONS VOTING RESULTS Tesla Proposals 1. A Tesla proposal to elect two Class II directors, James Murdoch and Kimbal Musk, to serve for a term of three years, or until th
Piper Sandler reiterated coverage of Tesla with a rating of Overweight and set a new price target of $310.00 from $300.00 previously
Deutsche Bank resumed coverage of Tesla with a rating of Buy and set a new price target of $295.00
Wolfe Research resumed coverage of Tesla with a rating of Peer Perform
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13D/A - Longeveron Inc. (0001721484) (Subject)
In the third quarter, we produced approximately 470,000 vehicles, delivered approximately 463,000 vehicles and deployed 6.9 GWh of energy storage products. Production Deliveries Subject to operating lease accounting Model 3/Y 443,668 439,975 3% Other Models 26,128 22,915 1% Total 469,796 462,890 3% Tesla will post its financial results for the third quarter of 2024 after market close on Wednesday, October 23, 2024. At that time, Tesla will issue a brief advisory containing a link to the Q3 2024 update, which will be available on Tesla's Investor Relations website. Tesla management will hold a live question and answer webcast that day a
Adjusted EBITDA Increased to $6.4 Million for the First Half of 2024 Conference Call and Webcast on September 16th at 8 AM ET NEW YORK, Sept. 16, 2024 /PRNewswire/ -- SunCar Technology Group Inc. (the "Company" or "SunCar") (NASDAQ:SDA), an innovative leader in cloud-based B2B software-focused auto services and auto e-insurance in China, today provided a business update and reported financial results for the first half of fiscal year 2024. First Half 2024 Financial Results Total revenue increased by 27% to $203.1 million for the six months ended June 30, 2024, from $159.4 million for the six months ended June 30, 2023.Auto Services ' revenue increased by 9% to $107.5 million for the six mo
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details: Conference Call Number:1.877.407.0789Conference ID:13747923Call me™ Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on the "Events & Presentations" sec
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)